Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Assertio Holdings, Inc. stock logo
ASRT
Assertio
$0.68
+0.9%
$0.65
$0.51
$1.80
$64.63M0.29568,688 shs125,871 shs
Bellerophon Therapeutics, Inc. stock logo
BLPH
Bellerophon Therapeutics
$0.01
$0.02
$0.01
$0.02
$147K0.7418,907 shs7,027 shs
CTI BioPharma Corp. stock logo
CTIC
CTI BioPharma
$9.09
$9.06
$4.01
$9.10
$1.20B0.834.50 million shsN/A
Monopar Therapeutics Inc. stock logo
MNPR
Monopar Therapeutics
$35.87
+2.0%
$36.12
$1.72
$54.30
$215.01M1.01360,767 shs24,007 shs
Oncolytics Biotech Inc. stock logo
ONCY
Oncolytics Biotech
$0.90
+14.4%
$0.54
$0.33
$1.53
$74.25M1.07675,700 shs1.54 million shs
(Almost)  Everything You Need To Know About The EV Market Cover

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Assertio Holdings, Inc. stock logo
ASRT
Assertio
+0.92%+4.62%+1.64%+8.58%-49.93%
Bellerophon Therapeutics, Inc. stock logo
BLPH
Bellerophon Therapeutics
0.00%0.00%0.00%0.00%-78.57%
CTI BioPharma Corp. stock logo
CTIC
CTI BioPharma
0.00%0.00%0.00%0.00%0.00%
Monopar Therapeutics Inc. stock logo
MNPR
Monopar Therapeutics
+2.02%+2.46%+11.71%+19.57%+919.90%
Oncolytics Biotech Inc. stock logo
ONCY
Oncolytics Biotech
+14.41%+25.14%+159.65%+81.95%-10.79%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Assertio Holdings, Inc. stock logo
ASRT
Assertio
1.7497 of 5 stars
3.50.00.00.01.40.81.3
Bellerophon Therapeutics, Inc. stock logo
BLPH
Bellerophon Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
CTI BioPharma Corp. stock logo
CTIC
CTI BioPharma
N/AN/AN/AN/AN/AN/AN/AN/A
Monopar Therapeutics Inc. stock logo
MNPR
Monopar Therapeutics
3.2035 of 5 stars
3.45.00.00.03.31.70.0
Oncolytics Biotech Inc. stock logo
ONCY
Oncolytics Biotech
1.2337 of 5 stars
3.43.00.00.00.00.00.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Assertio Holdings, Inc. stock logo
ASRT
Assertio
3.00
Buy$2.75303.82% Upside
Bellerophon Therapeutics, Inc. stock logo
BLPH
Bellerophon Therapeutics
0.00
N/AN/AN/A
CTI BioPharma Corp. stock logo
CTIC
CTI BioPharma
0.00
N/AN/AN/A
Monopar Therapeutics Inc. stock logo
MNPR
Monopar Therapeutics
2.80
Moderate Buy$56.5057.51% Upside
Oncolytics Biotech Inc. stock logo
ONCY
Oncolytics Biotech
2.75
Moderate Buy$4.33380.95% Upside

Current Analyst Ratings Breakdown

Latest ONCY, ASRT, CTIC, BLPH, and MNPR Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/23/2025
Monopar Therapeutics Inc. stock logo
MNPR
Monopar Therapeutics
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$60.00
5/21/2025
Oncolytics Biotech Inc. stock logo
ONCY
Oncolytics Biotech
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$5.00 ➝ $5.00
5/19/2025
Assertio Holdings, Inc. stock logo
ASRT
Assertio
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$3.50 ➝ $3.50
5/16/2025
Oncolytics Biotech Inc. stock logo
ONCY
Oncolytics Biotech
Jones Trading
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Hold
5/13/2025
Assertio Holdings, Inc. stock logo
ASRT
Assertio
Alliance Global Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy
(Data available from 7/4/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Assertio Holdings, Inc. stock logo
ASRT
Assertio
$124.96M0.52$0.05 per share13.75$1.27 per share0.54
Bellerophon Therapeutics, Inc. stock logo
BLPH
Bellerophon Therapeutics
$5.64M0.03N/AN/A$0.27 per share0.04
CTI BioPharma Corp. stock logo
CTIC
CTI BioPharma
$53M22.62N/AN/A($0.14) per share-64.93
Monopar Therapeutics Inc. stock logo
MNPR
Monopar Therapeutics
N/AN/AN/AN/A$9.02 per shareN/A
Oncolytics Biotech Inc. stock logo
ONCY
Oncolytics Biotech
N/AN/AN/AN/A$0.05 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Assertio Holdings, Inc. stock logo
ASRT
Assertio
-$21.58M-$0.32N/A22.70N/A-25.72%-24.87%-10.87%8/6/2025 (Estimated)
Bellerophon Therapeutics, Inc. stock logo
BLPH
Bellerophon Therapeutics
-$19.83M-$0.84N/AN/AN/AN/AN/AN/A
CTI BioPharma Corp. stock logo
CTIC
CTI BioPharma
-$92.99M-$0.58N/A26.74N/A-91.38%N/A-55.82%N/A
Monopar Therapeutics Inc. stock logo
MNPR
Monopar Therapeutics
-$15.59M-$3.48N/AN/AN/AN/A-55.39%-51.53%8/8/2025 (Estimated)
Oncolytics Biotech Inc. stock logo
ONCY
Oncolytics Biotech
-$23.14M-$0.29N/AN/AN/AN/A-313.77%-130.19%7/30/2025 (Estimated)

Latest ONCY, ASRT, CTIC, BLPH, and MNPR Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/14/2025Q1 2025
Oncolytics Biotech Inc. stock logo
ONCY
Oncolytics Biotech
-$0.09-$0.06+$0.03-$0.06N/AN/A
5/13/2025Q1 2025
Monopar Therapeutics Inc. stock logo
MNPR
Monopar Therapeutics
-$0.65-$0.38+$0.27-$0.38N/AN/A
5/12/2025Q1 2025
Assertio Holdings, Inc. stock logo
ASRT
Assertio
-$0.06-$0.14-$0.08-$0.14$27.52 million$26.49 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Assertio Holdings, Inc. stock logo
ASRT
Assertio
N/AN/AN/AN/AN/A
Bellerophon Therapeutics, Inc. stock logo
BLPH
Bellerophon Therapeutics
N/AN/AN/AN/AN/A
CTI BioPharma Corp. stock logo
CTIC
CTI BioPharma
N/AN/AN/AN/AN/A
Monopar Therapeutics Inc. stock logo
MNPR
Monopar Therapeutics
N/AN/AN/AN/AN/A
Oncolytics Biotech Inc. stock logo
ONCY
Oncolytics Biotech
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Assertio Holdings, Inc. stock logo
ASRT
Assertio
0.36
1.66
1.35
Bellerophon Therapeutics, Inc. stock logo
BLPH
Bellerophon Therapeutics
N/AN/AN/A
CTI BioPharma Corp. stock logo
CTIC
CTI BioPharma
N/A
1.27
1.26
Monopar Therapeutics Inc. stock logo
MNPR
Monopar Therapeutics
N/A
36.91
36.91
Oncolytics Biotech Inc. stock logo
ONCY
Oncolytics Biotech
N/A
3.20
3.20

Institutional Ownership

CompanyInstitutional Ownership
Assertio Holdings, Inc. stock logo
ASRT
Assertio
48.96%
Bellerophon Therapeutics, Inc. stock logo
BLPH
Bellerophon Therapeutics
10.61%
CTI BioPharma Corp. stock logo
CTIC
CTI BioPharma
91.45%
Monopar Therapeutics Inc. stock logo
MNPR
Monopar Therapeutics
1.83%
Oncolytics Biotech Inc. stock logo
ONCY
Oncolytics Biotech
6.82%
CompanyEmployeesShares OutstandingFree FloatOptionable
Assertio Holdings, Inc. stock logo
ASRT
Assertio
2095.78 million91.95 millionOptionable
Bellerophon Therapeutics, Inc. stock logo
BLPH
Bellerophon Therapeutics
2012.23 million11.60 millionNo Data
CTI BioPharma Corp. stock logo
CTIC
CTI BioPharma
127131.88 million121.84 millionOptionable
Monopar Therapeutics Inc. stock logo
MNPR
Monopar Therapeutics
106.12 million4.86 millionNot Optionable
Oncolytics Biotech Inc. stock logo
ONCY
Oncolytics Biotech
3094.28 million94.19 millionNot Optionable

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Assertio stock logo

Assertio NASDAQ:ASRT

$0.68 +0.01 (+0.92%)
Closing price 07/3/2025 03:11 PM Eastern
Extended Trading
$0.68 0.00 (0.00%)
As of 07/3/2025 04:47 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Assertio Holdings, Inc., a commercial pharmaceutical company, provides various products to patients in the United States. Its pharmaceutical products include INDOCIN, an oral and suppository solution for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis. It also provides Sympazan, a benzodiazepine for the adjunctive treatment of seizures related with lennox-gastaut syndrome in patients aged two years of age or older; CAMBIA, a non steroidal anti inflammatory drug (NSAID) for the treatment of migraine pain, nausea, photophobia, and phonophobia; Zipsor, a NSAID for relief of mild to moderate pain in adults; SPRIX, a NSAID for the short term management of moderate to moderately severe pain that requires analgesia at the opioid level; Otrexup, a single-dose auto-injector containing a prescription medicine and methotrexate that is used to treat patients with severe, active rheumatoid arthritis, and active polyarticular juvenile idiopathic arthritis, as well as treat adult with severe, recalcitrant, and disabling psoriasis; and ROLVEDON, a long-acting granulocyte colony-stimulating factor that is indicated to decrease the incidence of infection caused by febrile neutropenia. The company was formerly known as Assertio Therapeutics, Inc. and changed its name to Assertio Holdings, Inc. in May 2020. Assertio Holdings, Inc. was incorporated in 2020 and is headquartered in Lake Forest, Illinois.

Bellerophon Therapeutics stock logo

Bellerophon Therapeutics NASDAQ:BLPH

Bellerophon Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its primary product is INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension. The company engages in the development of INOpulse, which is in Phase 3 clinical trial for the treatment of pulmonary hypertension associated with fibrotic interstitial lung disease; which has completed Phase 2a clinical trial for pulmonary hypertension associated with chronic obstructive pulmonary disease; and that has completed Phase 2 dose escalation stage for pulmonary hypertension associated with sarcoidosis, as well as for chronic thromboembolic pulmonary hypertension and pulmonary hypertension associated with pulmonary edema from high altitude sickness. The company was formerly known as Ikaria Development LLC and changed its name to Bellerophon Therapeutics, Inc. in January 2014. Bellerophon Therapeutics, Inc. was founded in 2009 and is headquartered in Warren, New Jersey.

CTI BioPharma stock logo

CTI BioPharma NASDAQ:CTIC

CTI BioPharma Corp., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States. It offers VONJO (pacritinib), an an oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CSF1R for the treatment of adult patients with myelofibrosis. CTI BioPharma Corp. has license and collaboration agreement with Teva Pharmaceutical Industries Ltd. and S*BIO Pte Ltd. The company was formerly known as Cell Therapeutics, Inc. and changed its name to CTI BioPharma Corp. in May 2014. CTI BioPharma Corp. was incorporated in 1991 and is headquartered in Seattle, Washington.

Monopar Therapeutics stock logo

Monopar Therapeutics NASDAQ:MNPR

$35.87 +0.71 (+2.02%)
Closing price 07/3/2025 01:04 PM Eastern
Extended Trading
$35.87 0.00 (0.00%)
As of 07/3/2025 04:23 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer. The company also engages in developing Camsirubicin, an analog of doxorubicin, which is in Phase 1b clinical trial for the treatment of advanced soft tissue sarcoma; MNPR-101, a urokinase plasminogen activator receptor targeted antibody for the treatment of various cancers; MNPR-101 RIT, a radioimmunotherapeutic based on MNPR-101 for the potential treatment of cancer and severe COVID-19; and MNPR-202, an analog of camsirubicin to treat doxorubicin-and camsirubicin-resistant cancers. Monopar Therapeutics Inc. has collaborations with the Grupo Español de Investigación en Sarcomas for the development of camsirubicin in patients with advanced soft tissue sarcoma; NorthStar Medical Radioisotopes, LLC to develop radio-immuno-therapeutics targeting severe COVID-19; and the Cancer Science Institute of Singapore to evaluate the activity of MNPR-202 and related analogs in various types of cancer. The company was founded in 2014 and is headquartered in Wilmette, Illinois.

Oncolytics Biotech stock logo

Oncolytics Biotech NASDAQ:ONCY

$0.90 +0.11 (+14.41%)
Closing price 07/3/2025 03:58 PM Eastern
Extended Trading
$0.90 +0.00 (+0.44%)
As of 07/3/2025 04:43 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. It has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep, as well as with Roche Holding AG. The company was incorporated in 1998 and is headquartered in Calgary, Canada.